secwatch.observer — SEC 8-K summary
======================================

Issuer:     LeonaBio, Inc. (LONA)
CIK:        0001620463
Form:       8-K/A
Filed at:   2026-03-31T23:59:59+00:00
Accession:  0001193125-26-134097
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 9.01, 2.01, 1.01
LLM model:  deepseek-v4-flash:cloud@v2

LeonaBio files amended 8-K on Sermonix license, provides ELAINE-3 cost and timeline update
--------------------------------------------------------------------------------

- SEC granted waiver from providing Sermonix financial statements; license deal treated as business acquisition under Regulation S-X.
- Sermonix reported ELAINE-3 cash expenditures of $14M (2023), $12M (2024), $5M (2025 through Dec 18).
- LeonaBio expects $45M (2026) and $30M (2027) in ELAINE-3 cash spend; made ~$11M from Dec 18–31, 2025.
- ELAINE-3 protocol amended to increase sample size from 500 to up to 600; enrollment completion targeted Q4 2026, topline data H2 2027.
- License agreement grants LeonaBio exclusive rights to lasofoxifene for oncology outside Retained Territory.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1620463/000119312526134097/0001193125-26-134097-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1620463/000119312526134097/lona-20251218.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-134097

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer